Oncology / Other

Disease Group

Oncology / Other

Disease Group Profile

As ACRRU continues to grow, we expect to expand our research to every major disease group. In this section, we feature studies in several of our nascent disease group areas, including Melanoma and Brain.

Disease Group Leaders

  • TBD
  • TBD
  • TBD

Disease Group Clinical Trials

CAM20CV

RECOVER: Phase 2 Randomized, Double-Blind Trial Treating Hospitalized Patients with COVID-19 with Camostat Mesilate, a TMPRSS2 Inhibitor

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER) »

No posts found.
ACCRU-ITOG-1504

Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Resistant Differentiated Thyroid Cancers: A Phase II Study

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) »

CE.6

Neuro Oncology – A Randomized Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients

Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme »

MORAb-004-203-STS

Sarcoma – A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation (SOURCE) »

RU241210I

Thyroid/Endocrine – Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer »

RU241306I

Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Meta static Thyroid Cancers

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer »

RU261206I

Melanoma – Randomized Phase II Study of AB (nab-paclitaxel Abraxane, Bevacizumab) versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery »